Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture (Q40041296)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 January 2016

Language	Label	Description	Also known as
English	Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture	scientific article published on 27 January 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

1

0 references

1 reference

ORCID Public Data File 2021

author name string

Miche Rombouts

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Dorien M Schrijvers

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Wim Martinet

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Guido R Y De Meyer

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

27 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Vascular Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

80

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

50-58

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Mechanisms of acute coronary syndromes and their implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Stabilization of atherosclerotic plaques: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

The pleiotropic effects of statins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Pleiotropic effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Beneficial cardiovascular pleiotropic effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Mouse models for atherosclerosis and pharmaceutical modifiers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Stabilisation of atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Detection of functional matrix metalloproteinases by zymography.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Mechanisms of plaque stabilization with statins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Mechanisms that regulate macrophage burden in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Participatory role of natural killer and natural killer T cells in atherosclerosis: lessons learned from in vivo mouse studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Natural killer T cells accelerate atherogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Lymphocytes in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Statins as modulators of regulatory T-cell biology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Role of angiogenesis in cardiovascular disease: a critical appraisal.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Do structural differences in statins correlate with clinical efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.01.007

7 January 2021

Identifiers

10.1016/J.VPH.2016.01.007

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

release_r64n7viz4zd6hp3jgmowowbuoy

1 reference

https://api.fatcat.wiki/v0/release/r64n7viz4zd6hp3jgmowowbuoy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40041296&oldid=1882999562"